Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications
Cancer Cell · 2026-01 · 44 (1) · 50-76
DOI: 10.1016/j.ccell.2025.12.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Cell, 2026-01. Verfasst von Xiaolan Deng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA; Center for RNA Biology and Therapeutics, Beckman Re…. Hauptthemen laut MEDLINE: Neoplasms, RNA Processing, Post-Transcriptional, Transcriptome, Epigenesis, Genetic. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 327 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
The epitranscriptome, comprising over 170 distinct RNA modifications, represents a dynamic and multifaceted layer of gene regulation. These chemical marks such as N6-methyladenosine (m6A), 5-methylcytosine (m5C), and pseudouridine (Ψ) modulate RNA processing, localization, stability, and translation, shaping cell identity and stress responses. In cancer, RNA modifications integrate with oncogenic signaling networks to influence cancer cell proliferation, metabolism, immune evasion, stemness, and therapeutic resistance. Recent advances in detection technologies, functional perturbation tools, and spatial profiling have accelerated our understanding of the epitranscriptome's roles and the underlying mechanisms in malignancies. In this review, we provide a mechanistic framework connecting RNA modifications and regulators to the hallmarks of cancer. We highlight emerging insights into the interface between epitranscriptomic regulators and canonical cancer pathways and evaluate their potential as biomarkers and therapeutic targets. Together, these findings underscore RNA modification as a pivotal regulatory axis in cancer biology and a promising frontier for translational intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA; Center for RNA Biology and Therapeutics, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA. Electronic ad…
- Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA; Center for RNA Biology and Therapeutics, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China. Electronic address: wuhz@cmu.edu.cn.
- Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA; Center for RNA Biology and Therapeutics, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA; Irell and Man…
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Institutes of Health National Cancer Institute
Zitieren
APA
Deng, X., Wu, D., Zhao, Y., Qing, Y., Wu, H., & Chen, J. (2026). Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications. Cancer Cell, 44(1), 50-76. https://doi.org/10.1016/j.ccell.2025.12.001
Vancouver
Deng X, Wu D, Zhao Y, Qing Y, Wu H, Chen J. Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications. Cancer Cell. 2026;44(1):50-76. doi:10.1016/j.ccell.2025.12.001
BibTeX
@article{Deng2026,
author = {Deng, Xiaolan and Wu, Dong and Zhao, Yingqi and Qing, Ying and Wu, Huizhe and Chen, Jianjun},
title = {Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications},
journal = {Cancer Cell},
year = {2026},
volume = {44},
number = {1},
pages = {50--76},
doi = {10.1016/j.ccell.2025.12.001}
}
EUVIMED